NO20062041L - Fremgangsmater for fremstille forbindelser som kan anvendes som proteaseinhibitoere - Google Patents

Fremgangsmater for fremstille forbindelser som kan anvendes som proteaseinhibitoere

Info

Publication number
NO20062041L
NO20062041L NO20062041A NO20062041A NO20062041L NO 20062041 L NO20062041 L NO 20062041L NO 20062041 A NO20062041 A NO 20062041A NO 20062041 A NO20062041 A NO 20062041A NO 20062041 L NO20062041 L NO 20062041L
Authority
NO
Norway
Prior art keywords
methods
preparing compounds
protease inhibitors
compounds
formula
Prior art date
Application number
NO20062041A
Other languages
English (en)
Inventor
David John Kucera
Nabil Saeed
Robert William Scott
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20062041L publication Critical patent/NO20062041L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det beskrives fremgangsmåter for å fremstille forbindelser av formel (I) som er nyttige som inhibitorer av HIV protease enzymet. Foreliggende oppfinnelse vedrører også mellomforbindelser nyttige i fremstilling av forbindelsene i formel (I).
NO20062041A 2003-12-04 2006-05-08 Fremgangsmater for fremstille forbindelser som kan anvendes som proteaseinhibitoere NO20062041L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52747003P 2003-12-04 2003-12-04
US59135404P 2004-07-26 2004-07-26
PCT/IB2004/003810 WO2005054187A1 (en) 2003-12-04 2004-11-22 Methods of preparing compounds useful as protease inhibitors

Publications (1)

Publication Number Publication Date
NO20062041L true NO20062041L (no) 2006-06-01

Family

ID=34657228

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062041A NO20062041L (no) 2003-12-04 2006-05-08 Fremgangsmater for fremstille forbindelser som kan anvendes som proteaseinhibitoere

Country Status (10)

Country Link
US (1) US20050153903A1 (no)
EP (1) EP1692104A1 (no)
JP (1) JP2007513140A (no)
KR (1) KR20060097047A (no)
AU (1) AU2004295186A1 (no)
BR (1) BRPI0417248A (no)
CA (1) CA2547955A1 (no)
IL (1) IL175528A0 (no)
NO (1) NO20062041L (no)
WO (1) WO2005054187A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2002000136A (es) * 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
JP2006288864A (ja) * 2005-04-13 2006-10-26 Padoru:Kk 外科手術用の骨固定具
JP2021138694A (ja) 2020-03-06 2021-09-16 ファイザー・インク ＳＡＲＳ−ＣｏＶ−２複製を阻害し、コロナウイルス疾患２０１９を処置する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
US5644028A (en) * 1992-05-13 1997-07-01 Japan Energy Corporation Process for producing peptide derivatives and salts therefor
NZ248332A (en) * 1992-08-07 1995-01-27 Sankyo Co Hiv protease inhibitor and its use
US6222043B1 (en) * 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US6673772B2 (en) * 1999-01-14 2004-01-06 Sumitomo Pharmaceuticals Company Limited Dipeptide compounds and their use as antiviral agents
HN2002000136A (es) * 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
US7094909B2 (en) * 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Also Published As

Publication number Publication date
US20050153903A1 (en) 2005-07-14
KR20060097047A (ko) 2006-09-13
WO2005054187A1 (en) 2005-06-16
BRPI0417248A (pt) 2007-03-06
IL175528A0 (en) 2006-09-05
AU2004295186A1 (en) 2005-06-16
JP2007513140A (ja) 2007-05-24
CA2547955A1 (en) 2005-06-16
EP1692104A1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
WO2004062613A3 (en) Hiv integrase inhibitors
NO20062185L (no) Hepatitt C virus-inhibitorer
NO20071593L (no) Pyrimidinderivater
NO20074093L (no) Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
NO20066055L (no) Pyridinderivater
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MY140841A (en) Indozolone derivatives as 11b-hsd1 inhibitors
NO20071242L (no) Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
DE60334536D1 (de) Furylverbindungen
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
SE0103710D0 (sv) Compounds
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
WO2009140101A3 (en) Imidazopyridine compounds useful as mmp-13 inhibitors
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
TW200730511A (en) Chroman compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application